Pennsylvania drugmaker Zynerba Pharmaceuticals is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.
The FDA approved Cyberonics' pacemaker-like AspireSR generator to reduce seizures in patients with drug-resistant epilepsy. The generator is part of the company's VNS Therapy System.
UCB is hosting a hackathon focused on developing new tools to improve the day-to-day lives of people with epilepsy and their families, PMLiVE reports.
Medtronic has published detailed results for the first time of a 5-year trial for deep brain stimulation therapy in treatment-resistant epilepsy. The device giant has said that it will make another run at an FDA approval for its DBS device in that indication.
Investigators at Scripps Translational Science Institute say they have identified the genetic trigger for a rare and potentially lethal form of epilepsy.
Boston Children's Hospital has unveiled a new magnetoencephalography system that records, measures and maps electrical activity in an infant's brain which could be critical in understanding a number of disorders, including epilepsy.
Researchers at Northwestern University's Feinberg School of Medicine used a form of gene sequencing to identify mutations that appear to be behind a type of epilepsy disorder.
Epilepsy devicemaker NeuroSigma filed to raise up to $50 million in an IPO, while ReWalk--whose mobile exoskeletons were recently approved by the FDA--set IPO terms to raise $50 million.
NeuroPace's implantable neurostimulator will receive new technology add-on payments from the federal Centers for Medicare & Medicaid Services in recognition of its clinical benefits compared to older therapies for the treatment of uncontrolled epilepsy in adults.
A new epilepsy treatment from Belgian drugmaker UCB helped reduce the rate of seizures in a Phase III trial, the company said, setting the stage for an FDA application and a shot at widening its footprint in the field.